Dario Neri, co-founder, CEO and CSO, is giving a presentation to address the question on how to achieve the therapeutic dose at the tumor site with cytokine-based targeted products.

Roberto De Luca, Head of Antibody Therapeutics at Philogen, is also giving a presentation focused on the antibody-based delivery of interferons for cancer therapy.

See cytokine-immunotherapies website for more details.